GSK Pays US$66 M Upfront for Spero’s Late-Stage Antibiotic
By Lucy Haggerty
Pharma Deals Review: Vol 2022 Issue 9 (Table of Contents)
Published: 29 Sep-2022
DOI: 10.3833/pdr.v2022.i9.2724 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
Hoping to leverage its antibiotic expertise, GSK has agreed to pay US$66 M upfront to gain an exclusive license to commercialise Spero Therapeutics’ tebipenem HBr in all regions except for Japan and certain other Asian countries...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS